Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Follow-Up Questions
Adaptimmune Therapeutics PLC 的 CEO 是誰？
Mr. Adrian Rawcliffe 是 Adaptimmune Therapeutics PLC 的 Chief Executive Officer，自 2015 加入公司。
ADAP 股票的價格表現如何？
ADAP 的當前價格為 $0.0641，在上個交易日 decreased 了 67.96%。
Adaptimmune Therapeutics PLC 的主要業務主題或行業是什麼？
Adaptimmune Therapeutics PLC 屬於 Biotechnology 行業，該板塊是 Health Care
